These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11740219)

  • 1. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization.
    Novack GD; Evans R
    J Glaucoma; 2001 Dec; 10(6):483-6. PubMed ID: 11740219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real advantages of preservative-free preparations in special containers for long-term glaucoma therapy.
    Boles Carenini B; Boldrini E; Brogliatti B
    Acta Ophthalmol Scand Suppl; 2002; 236():57-9. PubMed ID: 12390147
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models.
    Daull P; Buggage R; Lambert G; Faure MO; Serle J; Wang RF; Garrigue JS
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):515-23. PubMed ID: 22671995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preservative-free treatment in glaucoma: who, when, and why.
    Stalmans I; Sunaric Mégevand G; Cordeiro MF; Hommer A; Rossetti L; Goñi F; Heijl A; Bron A
    Eur J Ophthalmol; 2013; 23(4):518-25. PubMed ID: 23483513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising concentrations of antimicrobial agents in pharmaceutical preparations: Case of an oral solution of glycerol and an ophthalmic solution containing cysteamine.
    Chan Hew Wai A; Becasse P; Tworski S; Pradeau D; Planas V
    Ann Pharm Fr; 2014 Nov; 72(6):415-21. PubMed ID: 25438652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension.
    Lambert O; Bandilla D
    Drug Des Devel Ther; 2012; 6():235-44. PubMed ID: 23049244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preservative exposure and surgical outcomes in glaucoma patients: The PESO study.
    Boimer C; Birt CM
    J Glaucoma; 2013 Dec; 22(9):730-5. PubMed ID: 23524856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tafluprost--a novel prostaglandin F2alpha analogue].
    Petrov SIu
    Vestn Oftalmol; 2014; 130(5):85-95. PubMed ID: 25711069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances in preservative-free glaucoma drops].
    Stefan C; Pop A; Cojocaru I
    Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ocular Surface Evaluation in Patients Treated with Prostaglandin Analogues Considering Preservative Agent].
    Mlčáková E; Mlčák P; Karhanová M; Langová K; Marešová K
    Cesk Slov Oftalmol; 2016; 72(4):120-127. PubMed ID: 27860477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States Food and Drug Administration and Department of Defense shelf-life extension program of pharmaceutical products: progress and promise.
    Khan SR; Kona R; Faustino PJ; Gupta A; Taylor JS; Porter DA; Khan M
    J Pharm Sci; 2014 May; 103(5):1331-6. PubMed ID: 24623105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
    Ammar DA; Noecker RJ; Kahook MY
    Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a study comparing the stability, efficacy, and adverse effect profile of innovator formulation, latanoprost (Xalatan) ophthalmic solution 0.005%, with that of a new formulation of a latanoprost ophthalmic solution containing cyclodextrins.
    Tressler CS; Bean GW
    J Clin Pharmacol; 2008 Jan; 48(1):123-4; author response 125-6. PubMed ID: 18094225
    [No Abstract]   [Full Text] [Related]  

  • 16. Preservatives in glaucoma medication.
    Steven DW; Alaghband P; Lim KS
    Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservative content in generic and brand name glaucoma eye drops.
    Hallaji NA; Rao PP; Trope GE
    Can J Ophthalmol; 2016 Dec; 51(6):492. PubMed ID: 27938964
    [No Abstract]   [Full Text] [Related]  

  • 18. New Candidate Preservative in Ophthalmic Solution Instead of Benzalkonium Chloride: 1,3-Didecyl-2-methyl Imidazolium Chloride.
    Iwasaki T; Uchiyama R; Nosaka K
    Chem Pharm Bull (Tokyo); 2023; 71(7):552-557. PubMed ID: 37394604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of temperature-controlled requirements into pharmacy practice.
    Ziance R; Chandler C; Bishara RH
    J Am Pharm Assoc (2003); 2009; 49(3):e61-7; quiz e68-9. PubMed ID: 19443313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
    Holló G; Topouzis F; Fechtner RD
    Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.